Author

Gemma Casals-Sendra

Institut d'Investigació en Ciències de la Salut Germans Trias i PujolORCID 0009-0009-4750-0145Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Ariadna Quer· 1 shared Conxi LázaroiD· 1 shared Eduard SerraiD· 1 shared Elisabeth CastellanosiD· 1 shared Emilio AmilibiaiD· 1 shared Ignacio BlancoiD· 1 shared Ignasi Jarne-SanziD· 1 shared Irene Boluda-Luis· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetics

Ariadna Quer

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

GeneticsMolecular Therapy — Nucleic AcidsPeer-reviewedAug 3, 2026

NF2 lacking exon 11 isoform induced by antisense gene therapy is able to recover partially merlin deficiency on NF2-related Schwannomatosis iPSC-derived spheroid model

Gemma Casals-Sendra, Ignasi Jarne-Sanz, Núria Catasús…·Elisabeth Castellanos

This study shows that antisense gene therapy using PMOs can induce exon 11 skipping in NF2-deficient Schwann cells, partially restoring merlin function and key pathways in a spheroid model of NF2-SWN.

DOI 10.1016/j.omtn.2026.103046

humanCRISPR screen

𝕏 PostBluesky